Retrospective Review Of Uveal Melanoma Patients Treated With Fractionated Stereotactic Radiotherapy
Abstract
Objectives: Last decades, radiotherapy displaced surgery as an effective organ preserving option for uveal melanoma treatment if tumor diameter and localisation permits. We aimed to report our experience about the management of uveal melanoma treated with CyberKnife fractionated stereotactic radiotherapy. Materials and Methods: We retrospectively evaluated 31 uveal melanoma patients treated with CyberKnife fractionated stereotactic radiotherapy. 29 was medium and 2 was large sized tumor. Results: The median follow-up was 26 months. Overall survival, metastasis free survival, local control and eye retention rates for 2- and 4-year were 94.7%, 94.7%; 89.1%, 81%; 92.9%, 81.3% and 82.1%, 61.9%, respectively. Conclusion: In view of our experience, it may be preferable to use CyberKnife fractionated stereotactic radiotherapy for patients with uveal melanoma as a noninvasive, precise radiotherapy technique.
Keywords
Kaynakça
- 1. Virgili G, Gatta G, Ciccolallo L,et al. Survival in patients with uveal melanoma in Europe. Arch Ophthalmol 2008; 126: 1413-8.
- 2. Singh AD, Topham A. Incidence of uveal melanoma in the United States:1973-1997. Ophthalmology 2003; 110: 956-61.
- 3. Greven KM, Greven CM. Orbital, ocular and optic nerve tumors. In: Tepper JE, Gunderson LL (ed). Clinical Radiation Oncology, third edn. Philedelphia: Elsevier Publishers, 2012; 535.
- 4. Zimmerman LE. Changing concepts concerning the malignancy of ocular tumors. Arch Ophthalmol 1967; 78: 166-73.
- 5. Freire JE, Kolton MM, Brady LW. Eye and Orbit. In: Halperin EC, Perez C , Brady LW (ed). Perez and Brady’s Principles and Practice of Radiation Oncology, fifth edn. Philadelphia: Lippincott Williams &Wilkins Publishers, 2008; 783.
- 6. Zimmerman LE, McLean IW, Foster WD. Statistical analysis of follow-up data concerning uveal melanomas, and the influence of enucleation. Ophthalmology 1980; 87: 557-64.
- 7. The Collaborative Ocular Melanoma Study Group: The COMS randomized trial of iodine-125 brachytherapy for choroidal melanoma, III: initial mortality findings. COMS Report No. 18. Arch Ophthalmol 2001; 119: 969-82.
- 8. The Collaborative Ocular Melanoma Study Group: The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma, V: Twelve-year mortality rates and prognostic factors. COMS Report No. 28. Arch Ophthalmol 2006; 124: 1684-93.
Ayrıntılar
Birincil Dil
İngilizce
Konular
Sağlık Kurumları Yönetimi
Bölüm
Araştırma Makalesi
Yazarlar
Ela Delikgöz Soykut
*
Türkiye
Yildiz Yukselen Guney
Türkiye
Aysen Dizman
Türkiye
Suheyla Aytac Arslan
Türkiye
Gokce Kaan Olcay
Türkiye
Mehmet Faik Cetindag
Türkiye
Rahmi Duman
Türkiye
Sibel Ozdogan
Yayımlanma Tarihi
29 Aralık 2018
Gönderilme Tarihi
21 Mayıs 2018
Kabul Tarihi
18 Aralık 2018
Yayımlandığı Sayı
Yıl 2018 Cilt: 40 Sayı: 4
Cited By
Therapy of Uveal Melanoma. A Review
Czech and Slovak Ophthalmology
https://doi.org/10.31348/2020/X10